
From: cara lansden/cambridge/biogen;nsf;cara.lansden@biogenidec.com;smtp

Sent: Wed Jun 14 2006 17:49:49 EDT

gilmore o'neill/cambridge/biogen@biogenidec;minhua yang/cambridge/biogen@biogenidec;

To:



samelli/cambridge/biogen@biogenidec;

Subject: Fw: BG12 MS IND

To the BG-12 MS CDT:

The BG-12 MS IND is no longer on clinical hold!!! Thank you all for your hard work in turning around the response so quickly.

Regards, Cara

Cara Lansden

Sr. Manager, Clinical Development Biogen Idec

Tel +617-679-2658 Fax +617-679-3518

Email: cara.lansden@biogenidec.com

---- Forwarded by Cara Lansden/Cambridge/Biogen on 06/14/2006 06:45 PM -----

Tammy Sarnelli/Cambridge/Biogen 14-Jun-2006 04:23 PM Message Size: 2.0 KB

To

BG-12 Program Team, Scott Stecher/Cambridge/Biogen@BiogenIdec

CC

Subject

BG12 MS IND



Hello everyone:

We were notified today by FDA that the clinical hold has been lifted! We are now free to begin the QTc study.

Thank you to all of you who worked so hard to make the submission quickly.

Sincerely Tammy

